Effect of genistein on replication of bovine herpesvirus type 1

American Journal of Veterinary Research

Volumn 63, Issue 8, 2002, Pages 1124-1128

  Akula, Shaw M ^a   Hurley, David J ^a   Wixon, Regina L ^a   Wang, Chungyang ^a   Chase, Christopher C L ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GENISTEIN; GLYCOPROTEIN E; ISOFLAVONE; PROTEIN TYROSINE KINASE; TAMOXIFEN;

ANIMAL CELL CULTURE; ANTIVIRAL ACTIVITY; ARTICLE; BOVINE HERPES VIRUS; CELL STRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECT; ESTROGEN ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INHIBITION KINETICS; INOCULATION; NONHUMAN; PROTEIN PHOSPHORYLATION; REACTION TIME; SOYBEAN; VIRUS REPLICATION;

ANIMALIA; BOS TAURUS; BOVINAE; BOVINE HERPESVIRUS 1; GLYCINE MAX; HERPES; HERPESVIRIDAE;

EID: 0036701803     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.1124     Document Type: Article

References (30)

1. Schwyzer M, Ackermann M. Molecular virology of ruminant herpesviruses. Vet Microbiol 1996;53:17-29.
2. Dingwell KS, Johnson DC. The herpes simplex virus gE-gI complex facilitates cell-to-cell spread and binds to components of cell junctions. J Virol 1998;72:8933-8942.
3. Yang M, Card JP, Tirabassi RS, et al. Retrograde, transneuronal spread of pseudorabies virus in defined neuronal circuitry of the rat brain is facilitated by gE mutations that reduce virulence. J Virol 1999;73:4350-4359.
4. Shaw AM, Braun L, Frew T, et al. A role for bovine herpesvirus 1 (BHV-1) glycoprotein E (gE) tyrosine phosphorylation in replication of BHV-1 wild-type virus but not BHV-1 gE deletion mutant virus. Virology 2000;268:159-166.
5. YuTa Y, Yoshida H, Sato M. Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase. Arch Virol 1993;132:451-461.
6. Favoreel HW, Nauwynck HJ, Pensaert MB. Role of the cytoplasmic tail of gE in antibody-induced redistribution of viral glycoproteins expressed on pseudorabies-virus-infected cells. Virology 1999;259:141-147.
7. Hodgson JM, Croft KD, Puddey IB, et al. Soybean isoflavonoids and their metabolic products inhibit in-vitro lipoprotein oxidation in serum. J Nutr Biochem 1996;7:664-669.
8. Brandi ML. Natural and synthetic isoflavones in the prevention and treatment of chronic diseases. Calcif Tissue Int 1996;61:S5-S8.
9. Bingham SA, Atkinson C, Liggine J, et al. Phyto-estrogens: Where are we now? Br J Nutr 1998;79:393-406.
10. Dean NM, Kanemitsu M, Boynton AL. Effects of the tyrosine-kinase inhibitor genistein on DNA synthesis and phospholipid-derived second messenger generation in mouse 10T1/2 fibroblasts and rat liver T51B cells. Biochem Biophys Res Commun 1989;165:795-801.
11. Levitzki A. Tyrphostins-potential antiproliferative agents and novel molecular tools. Biochem Pharmacol 1990;40:913-918.
12. Huang J, Nasr M, Kim J, et al. Genistein inhibits protein histidine kinase. J Biol Chem 1992;267:15511-15515.
13. Molteni A, Brizio-Molteni L, Persky V. In vitro hormonal effects of soybean isoflavones. J Nutr 1995;125(suppl 3):751S-756S.
14. Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 1997;27:31-40.
15. Booth C, Hargreaves DF, Hadfield JA, et al. Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro. Br J Cancer 1999;80:1550-1557.
16. Ishimi Y, Miyaura C, Ohmura M, et al. Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency. Endocrinology 1999;140:1893-1900.
17. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997:138:863-870.
18. Batra S. Effect of estrogen and progesterone treatment on calcium uptake by myometrium. and smooth muscle of the lower urinary tract. Eur J Pharmacol 1986;127:37-42.
19. Migliaccio A, Di Domenico M, Castoria G, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996;15:1292-1300.
20. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the c-AMP signaling pathway: stimulation of adenylate cyclase and c-AMP-regulated gene transcription. Proc Natl Acad Sci U S A 1994;91:8517-8521.
21. Marino M, Pallottini V, Trentalance A. Estrogens cause rapid activation of IP3-PKC- signal transduction pathway in HEPG2 cells. Biochem Biophys Res Commun 1998;245:254-258.
22. O'Brian CA, Liskamp RM, Solomon DH, et al. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985;45:2462-2465.
23. Gundimeda U, Chen Z, Gopalakrishna R, et al. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 1996;271:13504-13514.
24. Luo W, Sharif TR, Houghton PJ, et al. CGP 41251 and tamoxilen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Differ 1997; 11: 1225-1240.
25. Guvakova MA, Surmacze E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cell lines. Cancer Res 1997;13:2606-2610.
26. Chowdhury SI, Ross CS, Lee BJ, et al. Construction and characterization of a glycoprotein E gene-deleted bovine herpesvirus type 1 recombinant. Am J Vet Res 1999;60:227-232.
27. Chase CC, Carter-Allen K, Letchworth GJ. The effect of bovine herpesvirus type 1 glycoproteins gI and gIII on herpesvirus infections. J Gen Virol 1989;70:1561-1569.
28. Lappalainen K, Jaaskelainen I, Syrjanen K. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharmacol Res 1994;8:1127-1131.
29. Reed LJ, Muench H. A simple method of estimating 50% end point. Am J Hyg 1938;27:493-497.
30. Wang C, Ma Q, Pagadala S, et al. Changes of isoflavones during processing of soy protein isolates. J Am Oil Chem Soc 1998; 75:337-341.